-

Bruker Releases 2023 Sustainability Report

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today released its 2023 Sustainability Report, highlighting how Bruker’s spirit of ‘Innovation with Integrity’ is advancing science and technology, medicine and health, as well as safety and prosperity in a responsible, sustainable manner. The report also provides an overview of Bruker’s ESG strategy, initiatives and performance.

“We are pleased to introduce this inaugural 2023 Sustainability Report, which showcases our commitment to corporate social responsibility, transparency and progress in many high-impact ESG areas,” said Gerald Herman, Bruker’s Executive Vice President & CFO. “As a global innovation leader in cutting-edge scientific instruments, analytical technologies and life-science solutions, our scientists and engineers support scientific and medical researchers and advanced businesses around the world to better understand molecular, cell and disease biology, to measure and image complex systems, and search for new ways to improve our quality of life. We are especially proud to collaborate closely with many of our customers on ways to ensure a healthier, safer, and more sustainable future.”

Frank H. Laukien, Ph.D., Bruker’s President & CEO, added: “Our 2023 Sustainability Report highlights how Bruker solutions are helping scientists and technicians to address environmental challenges, advance disease research and scientific discovery, identify hazardous materials in our environment, secure the safety and authenticity of our food and materials, advance research and development of next-generation renewable energy technologies, and to improve recycling. It also reviews our initiatives to reduce environmental impact, promote social responsibility, diversity and inclusion, and to exercise the highest standards of corporate governance, all part of our long-term commitment to ‘Innovation with Integrity’.”

To access the Sustainability Report, and for more information regarding Bruker sustainability initiatives, please visit the Corporate Social Responsibility (CSR) section of our website at www.bruker.com/en/about/csr

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life-science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial research, semiconductor metrology and cleantech applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Joe Kostka
Associate Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Joe Kostka
Associate Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Announces $500 Million in Multi-Year Orders from Two Global Healthcare Companies for Supply of High-Performance Superconductors for MRI

HANAU, Germany--(BUSINESS WIRE)--The Bruker Energy & Supercon Technologies (BEST) division, a segment of Bruker Corporation (Nasdaq: BRKR), today announced two multi-year supply agreements for Bruker’s latest superconductors, which are used by global radiology companies to build their next generations of magnetic resonance imaging (MRI) magnets. The combined order value of the two agreements is approximately $500 million in expected future BEST revenues, with different agreement duration pe...

Bruker Consolidates Ownership of TOFWERK in Expansion of Mass Spectrometry Portfolio into New Applied Markets

THUN, Switzerland--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of an additional 60% ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker’s ownership to 100%. The transaction adds ultra-fast TOF-MS technology for small-molecule markets, including atmospheric chemistry research, air quality monitoring, exposomics, foods, flavors &a...

Bruker Corporation to Present at the J.P. Morgan Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 45th annual J.P. Morgan Healthcare Conference in San Francisco. Senior leadership will present on behalf of the Company on Monday, January 12th, 2026 at 9:00 AM Pacific Standard Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the “Events...
Back to Newsroom